Kawasaki syndrome (KS) is an acute vasculitis in children complicated by the development of heart disease. Despite its description over 50 years ago, the etiology of coronary artery disease in KS is unknown. High dose intravenous immunoglobulin is the most effective approach to reduce cardiovascular complications. It remains unclear why patients with KS develop coronary artery aneurysms. A subset of patients is resistant to immunoglobulin therapy. Given the heterogeneity of clinical features, variability of history, and therapeutic response, KS may be a cluster of phenotypes triggered by multiple infectious agents and influenced by various environmental, genetic, and immunologic responses. The cause of KS is unknown, and a diagnostic test remains lacking. A better understanding of mechanisms leading to acute KS would contribute to a more precision medicine approach for this complex disease. In the current viewpoint, we make the case for microbial superantigens as important causes of KS.

Introduction

Kawasaki syndrome (KS) is an acute multisystem vasculitis associated with immune activation and vascular endothelial dysfunction [1,2]. It is the leading cause of acquired heart disease in children throughout the world, with a particularly high prevalence in Asia. Despite its discovery over 50 years ago, the KS etiology and the pathogenesis of coronary artery aneurysms are unknown, but many potential causes and risk factors have been identified [3]. The combination of aspirin and high dose intravenous immunoglobulin (IVIG) is highly effective in reducing cardiovascular complications [4]. It remains unclear why only 25% of patients with KS develop coronary artery aneurysms and why a small subset of patients develop coronary artery disease despite IVIG treatment [5,6].

Given the heterogeneity of clinical features, variability of natural history, and therapeutic response, it is more accurate to refer to KS as a syndrome, capturing the likelihood we are dealing with a cluster of phenotypes triggered by multiple infectious agents and influenced by various environmental, genetic, and immunologic responses. A better understanding of mechanisms leading to acute KS would likely contribute to a more precision medicine approach for this complex syndrome. In the current review, we make the case for microbial superantigens as significant causes of KS.

Clinical features of KS

The diagnosis of acute KS is based on clinical criteria defined by the American Heart Association [1]. This includes the presence of fever, bilateral nonexudative conjunctival injection, inflammation of the oropharyngeal mucosa, erythema of the palms or soles during acute KS or periungual desquamation during convalescent KS, and cervical lymphadenopathy. In atypical cases, patients with fever and fewer principal

Abbreviations

IVIG, intravenous immunoglobulin; KS, Kawasaki syndrome; SEs, staphylococcal enterotoxins; SPEs, streptococcal pyrogenic exotoxins; TSST-1, staphylococcal TSS toxin-1; Vβ-TCR, variable part of the β-chain of the T lymphocyte receptor.
symptoms can be called KS when coronary artery disease is detected.

Kawasaki syndrome has a variety of clinical features which overlap with various infectious diseases. The differential diagnosis includes staphylococcal or streptococcal scarlet fever or toxic shock syndrome (TSS), staphylococcal scalded skin syndrome, and juvenile rheumatoid arthritis [7]. Since KS is based on clinical criteria that overlap with other illnesses, diagnostic uncertainties can arise [8].

**Cardiovascular manifestations**

Cardiovascular findings are characteristic of KS [9–11]. Coronary artery aneurysms occur in approximately 25% of untreated patients. A subset of patients also suffers from aortic or mitral regurgitation due to myocardial involvement.

**Laboratory findings in KS**

During acute KS, patients develop neutrophilia [12]. Neutrophil activation has been linked to coronary artery involvement in KS [13]. Thrombocytosis is common [14]. Early in KS, C-reactive protein and erythrocyte sedimentation rate are increased [15].

Vascular endothelial damage is observed early in the development of coronary artery disease [16–18]. Acute KS is characterized by activation of lymphocytes and monocyte/macrophages activation [19–21]. There are also increased levels of IL-1, TNF-α, and IL-6, and these cytokines correlate with development of coronary artery disease and IVIG nonresponsiveness [15,22,23]. Gene association studies have implicated polymorphisms in IL-1, TNF-α, IL-6, HLA, and Toll-like receptors indicative of immune responses in KS [24–28]. Finally, treatment of patients with IVIG and aspirin reduces the immune activation associated with this syndrome [29,30]. Importantly, IVIG contains high titers of neutralizing antibodies to microbial superantigens which we have implicated in acute KS. Successful management of patients who are IVIG-resistant with immunosuppressive agents such as corticosteroids, cyclosporin, infliximab, and IL-1 antagonists reinforces the concept that KS is immune-mediated [31–35].

Identification of the etiologic agent(s) triggering KS is key to developing a specific diagnostic test and more effective approaches for the prevention and treatment of KS. Nevertheless, many physicians believe that KS is caused by an infectious agent. Furthermore, the clinical findings in acute KS significantly overlap with bacterial toxin-mediated diseases such as TSS.

The immune activation found in acute KS is characteristic of diseases caused by bacterial superantigens [36]. Staphylococcal TSS toxin-1 (TSST-1) and streptococcal pyrogenic exotoxins (SpeS) are well-known superantigens that cause massive stimulation of T cells. Characteristic of superantigens, these bacterial toxins bind directly to amino acid residues outside of the peptide binding groove and selectively stimulate T cells expressing T-cell antigen receptor (TCR) β-chain variable gene segments (Vβ-TCRs). In contrast, nominal peptide antigens only stimulate a small proportion of T cells.

To determine whether acute KS is caused by superantigen(s), their T cells have been analyzed for Vβ-TCR expression [37]. Acute KS was associated with Vβ2 T-cell expansion. In contrast, cells from control subjects showed no expansion of Vβ2-positive T cells. During the convalescence phase of KS, percentages of Vβ2-positive returned to normal. This expansion of Vβ2-positive T cells is similar to the changes observed in TSS [36]. Since this report, there have been other reports of Vβ2 expansion in KS [38–41]. Interestingly, Yamashiro et al. [42] have also observed increased Vβ2 T cells in the small intestines of children with acute KS. Abe et al. [43] have also analyzed the sequences of Vβ2 gene segments from patients with acute KS. None of the acute KS Vβ2-positive T-cell clones had evidence of clonotypic expansion which is consistent with superantigen stimulation.

T. Kawasaki provided in coded fashion 10 acute and 10 convalescent sera from KS patients to P. M. Schlievert. These were from KS children and thus could not be called adult KS or TSS. When the code was broken for the serum samples, 0/10 acute sera and 5/10 convalescent sera had protective antibodies to TSST-1 (P < 0.03). One acute serum was borderline positive and became negative upon convalescence. The data also examined the response simultaneously to three superantigens where no clear pattern was observed [44]. The data indicated that at least five of the children were exposed to TSST-1 during the acute KS phase. It has been shown that infants of 2–3 months age lack antibodies to TSST-1 [45]. Parsonnet et al. [46,47] showed that 20% of human populations, including those of Asian descent where KS appears more common, cannot develop protective antibodies. It is thus possible that the lack of development of antibodies from acute KS to convalescence in half the subjects tested resulted in part from the inability of humans to make antibody responses to TSST-1. It has also been shown, like menstrual TSS [48], recurrences of KS occur, although less commonly (approximately 40% for menstrual TSS, compared to 2% for KS) [49].
Leung et al. later [50] analyzed patients with acute KS and compared them to control subjects. Superantigen-producing bacteria were found in the majority of patients with acute KS but rarely in the controls ($P < 0.0001$). Of 13 superantigen-positive cultures from patients with KS, 11 were TSST-1-secreting *Staphylococcus aureus*, and 2 were Group A streptococci producing SpeB and SpeC. Interestingly, TSST-1 and SpeC are known to stimulate V$\beta$2 T cells. Of note, 12 of the 13 culture-positive patients had superantigen-producing *S. aureus* isolated from the pharyngeal or rectal cultures consistent with the concept infection in KS patients begins in the gastrointestinal tract.

A follow-up, double-blinded, six medical center, case–control study was performed [51]. There were 45 acute KS children and 37 febrile matched controls in the study. Cultures from throat, nares, axilla, and perirectal areas were obtained and evaluated independently by both the home medical center diagnostic laboratories and the Schlievert laboratory. When all major staphylococcal and streptococcal superantigens were compared as a group, there was no significant difference observed in superantigen presence between KS cases and febrile controls ($P = 0.078$). However, focusing on those superantigens that skew V$\beta$2-TCRs, there was a significant association of TSST-1 and SpeC with KS compared to the febrile controls ($P = 0.019$). These data support the role of *S. aureus* producing TSST-1 and Group A streptococci producing SpeC in KS.

An additional potentially important finding in the above study was that the Schlievert laboratory was able to isolate TSST-1 producing *S. aureus* and Group A streptococci producing SpeC, whereas the home medical center diagnostic laboratories in general did not find either microbe [51]. The possible difference between the laboratories included the longer time the Schlievert laboratory retained the cultures, allowing TSST-1 and SpeC superantigen-producing bacteria, to grow on blood agar. Many of these strains were inhibited on blood agar for 4–5 days by normal microbicide organisms from mucosal surfaces, and some were slow-growing, though not small colony variants.

As discussed above, acute KS and TSS overlap in many features, including fever, erythematous rash, and peripheral edema. Indeed, TSS was originally called adult KS [52,53]. However, most investigators suggest there are two major criteria that distinguish KS from TSS: (a) KS has associated aneurysm development but not TSS, and (b) conversely, KS lacks hypotension which typifies TSS. These differences are now being blurred. For example, probable TSS is defined by the CDC as TSS with one major criterion absent [54–56]. Cases that fit the criteria of probable TSS without hypotension have been described as far back as the early 20th century [57]. Some investigators, including Todd et al. [58], who named TSS, have described cases of KS superimposed on TSS [59]. Additionally, there have been multiple reports of a KS-shock syndrome [60,61].

Besides the above formal studies, P. M. Schlievert received 27 *S. aureus* isolates from KS children. All of these isolates, as submitted in blinded fashion, produced TSST-1.

### COVID-19 and KS/TSS

Once the number of cases of COVID-19 was apparently high enough, a rare KS/TSS-like syndrome was described. This syndrome, also known as multisystem inflammatory syndrome or pediatric inflammatory multisystem syndrome, was well-studied by Whittaker et al. [62]. In the study, 58 children were assessed for the new syndrome with comparisons to KS and TSS. It was noted that 78% of cases had evidence of COVID-19 infection prior to development of the new syndrome. All children had fever and variable nonspecific symptoms, including vomiting, diarrhea, and abdominal pain. They all showed marked inflammation. Of the 58 cases, 52% had a rash, 45% showed conjunctival injection, and 50% developed shock. Thirteen met the American Heart Association definition of KS. The average age of the children was approximately 9, which is older than children with typical KS. The onset of the new syndrome was 4–5 weeks after the peak occurrence of COVID-19.

There are large numbers of studies ongoing to examine this new syndrome, but its direct cause remains unclear. This new syndrome, KS, and TSS have all been described as ‘cytokine storm’ syndromes, with massive overproduction of cytokines [36,63].

### Conclusions and future directions

There has been an enormous amount of effort expended to find the cause of KS, and thus far, the cause remains unknown. However, because of many similarities between KS and TSS, we hypothesize that TSST-1 *S. aureus* may be a significant cause. Like in KS, TSS as caused by TSST-1 is a vasculitis with a massive cytokine response. This cytokine response, sometimes called a ‘cytokine storm’, likely explains the majority of features of both syndromes. IVIG, as used to manage patients with KS, and occasionally TSS, has protective antibodies against TSST-1 and other staphylococcal and streptococcal superantigens. Very recent studies of the COVID-19 KS/TSS-like syndrome is also...
Kawasaki syndrome and superantigens

considered a ‘cytokine storm’ and could be induced either by the SARS-CoV-2 virus alone or by secondary infections, such as by TSST-1 S. aureus. Figure 1 summarizes the clinical features of KS and TSS.

It is clear from our discussion that the features of KS and staphylococcal TSS, induced by TSST-1, overlap in many respects. These are listed in Table 1. Some clinicians focus on the rash, with some thinking there is a difference, but others unable to tell the difference. It is a consensus that TSST-1-induced TSS has hypotension as a defining criterion, though this may not be observed in milder cases. The hypotension of TSS results from a vascular capillary leak syndrome caused principally by cytokines, especially TNF. Both KS and TSS are vasculitis diseases. Recently, the new syndrome related to KS and TSS has been described in detail; its association with COVID-19 infection is well-documented but occurs 4–5 weeks post-COVID-19 [62]. The best therapy for this new syndrome could be determined once the precise cause is established. Use of IVIG would neutralize the possible known superantigens, including staphylococcal enterotoxin B, which appears structurally related to SARS-CoV-2 spike proteins.

There are at least three types of experiments that need to be done that may resolve whether or not superantigens are the principal causes of KS. It is already established that superantigens cause TSS [36]. Investigators argue that KS occurs without the need of antibiotic therapy. Lack of responsiveness to antibiotic at one time was stated as a major finding in KS. TSS patients do respond to antibiotics, but there is a high recurrence rate, suggesting incomplete antibiotic clearance of the causative S. aureus [48]. Investigators have argued that they do not isolate S. aureus or Group A streptococci from KS cases. The multicenter, double-blinded type of study performed by Leung et al. [51] should be repeated by other investigators, retaining and examining all bacteria culture plates for seven days. This should be done for both KS patients and matched, febrile controls.

Second, it will help in clarifying KS causation if TSST-1 producing S. aureus can be used to produce

| Characteristic                      | KS         | TSS         |
|-------------------------------------|------------|-------------|
| Fever                              | ++         | +           |
| Conjunctival injection              | +          | +           |
| Mucous membrane changes             | +          | +           |
| Erythematous rash                   | +          | +           |
| Peripheral edema                    | +          | +           |
| Cervical lymphadenopathy            | +          | +           |
| Vasculitis                          | +          | +           |
| Vβ2 skewing                         | +          | +           |
| TSST-1 *Staphylococcus aureus* or SpeC group A streptococci | Significant +; not 100% | + |
| Hypotension                         | – a        | +           |
| Coronary artery aneurysms           | May be present | – |
| ‘Cytokine storm’ disease            | +          | +           |
| Age                                 | < 4 years  | All ages    |
| Recurrences                         | 2%         | At least 40%|

*aHypotension is present in KS-Shock syndrome.

Fig. 1. Kawasaki syndrome (KS) and toxic shock syndrome (TSS) are ‘cytokine storms’ that result in overlapping clinical features due to vasculitis associated with massive cytokine production. Massive cytokine production results in high fever, red skin rash and reddened mucous membranes, cervical lymph node swelling, and edema of the hands and feet.
aneurysms and other KS changes in an animal model, for example the rabbit, administered TSST-1 in subcutaneous miniosmotic pumps [64,65]. These pumps are designed to release a certain amount of TSST-1 for 7–28 days. It may be that mice could be used as an alternative. Both models merit consideration.

Recently, there have been news media reports of COVID-19 infection in children who appear to have KS or TSS symptoms. These cases are now commonly referred to as pediatric inflammatory multisystem syndrome. Third, it is important to examine these children referred to as pediatric inflammatory multisystem syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [36].

Acknowledgements

The authors acknowledge Nicole Meiklejohn for her assistance in preparing this manuscript. This work was supported by The 5R01 HL37260 grant from NHLBI and a generous gift by The Ann and Louis Rudolph Kawasaki Disease Research Fund at National Jewish Health.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

DYML and PMS conceived and wrote the manuscript and prepared the table and figure.

References

1 McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB et al. (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135, e927–e999.

2 Burns JC (2019) New perspectives on Kawasaki disease. Arch Dis Child 104, 616–617.

3 Kawasaki T (1967) [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 16, 178–222.

4 de Graeff N, Groot N, Brogan P, Ozen S, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P et al. (2019) European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. Rheumatology (Oxford) 58, 656–671.

5 Burns JC, Hoshino S & Kobayashi T (2018) Kawasaki disease: an essential comparison of coronary artery aneurysm criteria. Lancet Child Adolesc Health 2, 840–841.

6 Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP et al. (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315, 341–347.

7 Hao S, Ling XB, Kanegaye JT, Bainto E, Dominguez SR, Heizer H, Jone PN, Anderson MS, Jaggi P, Baker A et al. (2020) Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses. Arch Dis Child 105, 772–777.

8 Cameron SA, Carr M, Pahl E, DeMarais N, Shulman ST & Rowley AH (2019) Coronary artery aneurysms are more severe in infants than in older children with Kawasaki disease. Arch Dis Child 104, 451–455.

9 Burns JC & Matsubara T (2018) New insights into cardiovascular disease in patients with Kawasaki disease. Curr Opin Pediatr 30, 623–627.

10 Abrams JY, Belay ED, Uehara R, Maddox RA, Schonberger LB & Nakamura Y (2017) Cardiac complications, earlier treatment, and initial disease severity in Kawasaki disease. J Pediatr 188, 64–69.

11 Brogan P, Burns JC, Cornish J, Diwakar V, Eleftheriou D, Gordon JB, Gray HH, Johnson TW, Levin M, Malik I et al. (2020) Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart 106, 411–420.

12 Wu G, Yue P, Ma F, Zhang Y, Zheng X & Li Y (2020) Neutrophil-to-lymphocyte ratio as a biomarker for predicting the intravenous immunoglobulin-resistant Kawasaki disease. Medicine (Baltimore) 99, e18535.

13 Lee SH, Ko KO, Lim JW, Yoon JM, Song YH, Lee JW & Cheon EJ (2019) Delta-neutrophil index: a potential predictor of coronary artery involvement in Kawasaki disease by retrospective analysis. Rheumatol Int 39, 1955–1960.

14 Zheng X, Wu W, Zhang Y & Wu G (2019) Changes in and significance of platelet function and parameters in Kawasaki disease. Sci Rep 9, 17641.

15 Nandi A, Pal P & Basu S (2019) A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study. Rheumatol Int 39, 1797–1801.

16 Ueno K, Ninomiya Y, Hazeki D, Masuda K, Nomura Y & Kawano Y (2017) Disruption of endothelial cell homeostasis plays a key role in the early pathogenesis.
of coronary artery abnormalities in Kawasaki disease. Sci Rep 7, 43719.
17 Jia C, Zhang J, Chen H, Zhuge Y, Chen H, Qian F, Zhou K, Niu C, Wang F, Qiu H et al. (2019) Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathepsin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis 10, 778.
18 Takahashi K, Oharaseki T & Yokouchi Y (2018) Histopathological aspects of cardiovascular lesions in Kawasaki disease. Int J Rheum Dis 21, 31–35.
19 Ohashi R, Fukazawa R, Shimizu A, Ogawa S, Ochi M, Nitta T & Itoh Y (2019) M1 macrophage is the predominant phenotype in coronary artery lesions following Kawasaki disease. Vasc Med 24, 484–492.
20 Xu M, Jiang Y, Wang J, Liu J, Liu C, Liu D & Yang S (2019) Distinct variations of antibody secreting cells and memory B cells during the course of Kawasaki disease. BMC Immunol 20, 16.
21 Xu M, Jiang Y, Zhang J, Zheng Y, Liu D, Guo L & Yang S (2018) Variation in IL-21-secreting circulating CD8+ T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Clin Chim Acta 471, 76–80.
22 Dusser P & Kone-Paut I (2017) IL-1 Inhibition may have an important role in treating refractory Kawasaki disease. Front Pharmacol 8, 163.
23 Ferdosian F, Dastgheib SA, Hosseini-Jangjou SH, Nafei Z, Lookzadeh MH, Noorishadkam M, Mirjalili SR & Neamatzadeh H (2019) Association of TNF-alpha rs1800629, CASP3 rs72689236 and FCGR2A rs1801274 polymorphisms with susceptibility to Kawasaki disease: a comprehensive meta-analysis. Fetal Pediatr Pathol 39, 1–17.
24 Shimizu C, Kim J, Eleftherohorinou H, Wright VJ, Hoang LT, Tremoulet AH, Franco A, Hibberd ML, Takahashi A, Kubo M et al. (2019) HLA-C variants associated with amino acid substitutions in the peptide binding groove influence susceptibility to Kawasaki disease. Hum Immunol 80, 731–738.
25 Xie X, Shi X & Liu M (2018) The roles of genetic factors in Kawasaki disease: a systematic review and meta-analysis of genetic association studies. Pediatr Cardiol 39, 207–225.
26 Fu LY, Qiu X, Deng QL, Huang P, Pi L, Xu Y, Che D, Zhou H, Lu Z, Tan Y et al. (2019) The IL-1B gene polymorphisms rs16944 and rs143627 contribute to an increased risk of coronary artery lesions in Southern Chinese children with Kawasaki disease. J Immunol Res 2019, 4730507.
27 Kim J, Shimizu C, Kingsmore SF, Veeraraghavan N, Levy E, Ribeiro Dos Santos AM, Yang H, Flatley J, Hoang LT, Hibberd ML et al. (2017) Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. PLoS One 12, e0170977.
28 Leung DY, Burns JC, Newburger JW & Geha RS (1987) Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79, 468–472.
29 Leung DY, Schlievert PM & Meissner HC (1998) The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 41, 1538–1547.
30 Burns JC, Kone-Paut I, Kuijpers T, Shimizu C, Tremoulet A & Arditi M (2017) Review: Found in translation: International initiatives pursuing Interleukin-1 blockade for treatment of acute Kawasaki disease. Arthritis Rheumatol 69, 268–276.
31 Dhanrajani A & Yeung RSM (2017) Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease. Curr Opin Rheumatol 29, 547–552.
32 Owens S, Agyeeman P, Whyte M, Crossland D, Flood T & Abinun M (2017) Aggressive anti-inflammatory treatment for refractory Kawasaki disease. J Infect 74, 91–95.
33 Wardle AJ, Connolly GM, Seager MJ & Tulloh RM (2017) Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 1, CD011188.
34 Guillaume MP, Reumaux H & Dubos F (2018) Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. Cardiol Young 28, 739–742.
35 Spaulding AR, Salgado-Pabón W, Kohler PL, Horswill AR, Leung DY & Schlievert PM (2013) Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26, 422–447.
36 Abel J, Kotzin BL, Juo K, Melish ME, Glode MP, Kohsaka T & Leung DY (1992) Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 89, 4066–4070.
37 Curtis N, Zheng R, Lamb JR & Levin M (1995) Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 72, 308–311.
38 Curtiss N, Zheng R, Lamb JR & Levin M (1995) Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 72, 308–311.
39 Leung DY, Giorno RC, Kazemi LV, Flynn PA & Busse JB (1995) Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 155, 5018–5021.
40 Pietra BA, De Inciencio J, Giannini EH & Hirsch R (1994) TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 153, 1881–1888.
Takeuchi T, Koike M et al. (1999) Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. *Immunology 96*, 465–472.

42 Yamashiro Y, Nagata S, Oguchi S & Shimizu T (1996) Selective increase of V beta 2+ T cells in the small intestinal mucosa in Kawasaki disease. *Pediatr Res 39*, 264–266.

43 Abe J, Kotzin BL, Meissner C, Melish ME, Takahashi M, Fulton D, Romagne F, Malissen B & Leung DY (1993) Characterization of T cell repertoire changes in acute Kawasaki disease. *J Exp Med 177*, 791–796.

44 Bell DM, Brink EW, Nitzkin JL, Hall CB, Wulff H, Berkowitz ID, Feorino PM, Holman RC, Huntley CL, Meade RH III et al. (1983) Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. *Clin Microbiol Rev 1*, 1 among healthy Japanese women.

45 Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL et al. (2005) Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing strains of *Staphylococcus aureus* and antibody to TSST-1 among healthy Japanese women. *J Clin Microbiol 46*, 2731–1881.

46 Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL et al. (2005) Prevalence of toxic shock syndrome toxin 1 (TSST-1) among healthy Japanese women. *J Clin Microbiol 46*, 2731–1881.

47 Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL et al. (2005) Prevalence of toxic shock syndrome toxin 1 (TSST-1) among healthy Japanese women. *J Clin Microbiol 46*, 2731–1881.

48 Osterholm MT, Davis JP & Bergdoll MS (1983) Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome.

49 Goswami N, Marzan K, De Oliveira E, Wagner-Lees S & Szmuszkovicz J (2018) Recurrent Kawasaki disease: a case report of three separate episodes at >4-year intervals. *Children (Basel) 5*, 155.

50 Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL & Schlievert PM (1993) Toxic shock syndrome toxin secreting *Staphylococcus aureus* in Kawasaki syndrome. *Lancet 342*, 1385–1388.

51 Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, Myones BL, Wheeler JG, Ruthazer R & Schlievert PM (2002) Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. *J Pediatr 140*, 742–746.

52 Schlossberg D, Kandra J & Kreiser J (1979) Possible Kawasaki disease in a 20-year-old woman. *Arch Dermatol 115*, 1435–1436.

53 Schlievert PM & Davis CC (2020) Device-associated menstrual toxic shock syndrome. *Clin Microbiol Rev 33*, e0032-19.

54 Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY & Broome CV (1982) Nonmenstrual toxic shock syndrome: a review of 130 cases. *Ann Intern Med 96*, 871–874.

55 Bartlett P, Reingold AL, Graham DR, Dan BB, Selinger DS, Tank GW & Wichertman KA (1982) Toxic shock syndrome associated with surgical wound infections. *JAMA 247*, 1448–1450.

56 Reingold AL, Dan BB, Shands KN & Broome CV (1982) Toxic-shock syndrome not associated with menstruation. A review of 54 cases. *Lancet 1*, 1–4.

57 Aranow H & Wood WB (1942) Staphylococcal infection simulating scarlet fever. *J Am Med Assoc 119*, 1491–1495.

58 Todd J, Fishhut M, Kapral F & Welch T (1978) Toxic-shock syndrome associated with phage-group-I staphylococci. *Lancet 2*, 1116–1118.

59 Wiesenthal AM & Todd JK (1984) Toxic shock syndrome in children aged 10 years or less. *Pediatrics 74*, 112–117.

60 Cakan M, Gemici H, Aktyay-Ayaz N, Keskindemirci G, Boruna H, Ikizoglu T & Celiker A (2016) Kawasaki disease shock syndrome: a rare and severe complication of Kawasaki disease. *Turk J Pediatr 58*, 415–418.

61 Kanegaye JT, Wilder MS, Molkara D, Fraizer JR, Pancheri J, Tremoulet AH, Watson VE, Best BM & Burns JC (2009) Recognition of a Kawasaki disease shock syndrome. *Pediatrics 123*, e783–e789.

62 Whittaker E, Bamford A, Jenny K, Kafourou M, Jones CE, Shah P, Ramnarayan P, Fraisse A, Miller O, Davies P et al. (2020) Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. *JAMA 324*, 259–269.

63 Brosnahan AJ & Schlievert PM (2011) Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome. *FEBS J 278*, 4649–4667.

64 Lee PK, Deringer JR, Kreiswirth BN, Novick RP & Schlievert PM (1991) Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins. *Infect Immun 59*, 879–884.

65 Vu BG, Stach CS, Kulhankova K, Salgado-Pabon W, Klingelhutz AJ & Schlievert PM (2015) Chronic superantigen exposure induces systemic inflammation, elevated bloodstream endotoxin, and abnormal glucose tolerance in rabbits: possible role in diabetes. *MBio 6*, e02554.

66 MacDonald KL, Osterholm MT, Hedberg CW, Schrock CG, Peterson GF, Jentzen JM, Leonard SA & Schlievert PM (1987) Toxic shock syndrome. A newly recognized complication of influenza and influenza-like illness. *JAMA 257*, 1053–1058.